Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WOBURN, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT THE FINAL PATIENT IN ITS PHASE 2B CLINICAL TRIAL EVALUATING AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS (AV) COMPLETED PARTICIPATION ON AUGUST 22, 2025.

BIOFRONTERA INC. ANNOUNCES LAST-PATIENT-OUT IN PHASE 2B STUDY OF AMELUZ (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS

WOBURN, MA, AUG. 13, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ:BFRI) (THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY IN DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE.

BIOFRONTERA INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

WOBURN, MA, AUG. 11, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (THE COMPANY), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THE APPOINTMENT OF GEORGE JONES AS CHIEF COMMERCIAL OFFICER (CCO), STARTING AUGUST 25, 2025. IN THIS ROLE, MR. JONES WILL OVERSEE THE COMPANY'S COMMERCIAL FUNCTIONS, INCLUDING SALES, MARKETING, AND MARKET ACCESS. HE WILL REPORT DIRECTLY TO CEO DR. HERMANN LUEBBERT.

BIOFRONTERA INC. APPOINTS GEORGE JONES AS CHIEF COMMERCIAL OFFICER

WOBURN, MA, AUG. 04, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC., (NASDAQ:BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION OF DERMATOLOGICAL PRODUCTS, ANNOUNCES IT WILL REPORT FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 ON WEDNESDAY, AUGUST 13, 2025. THE RESULTS WILL BE RELEASED AFTER THE MARKET CLOSE ON WEDNESDAY, AUGUST 13 AND THE COMPANY WILL HOST A CONFERENCE CALL ON THURSDAY, AUGUST 14 AT 10:00AM EASTERN TIME.

BIOFRONTERA INC. TO REPORT SECOND QUARTER FY 2025 FINANCIAL RESULTS ON AUGUST 13, 2025

BIOFRONTERA INC. HAS SIGNED AN AGREEMENT TO ACQUIRE ALL US ASSETS RELATED TO AMELUZ AND RHODOLED INCLUDING NEW DRUG APPLICATION (NDA) AND ASSOCIATED PATENTS FROM GERMANY-BASED BIOFRONTERA AG. UNDER THEIR NEW AGREEMENT, THE EFFECTIVE ROYALTY RATE PAID BY BIOFRONTERA INC. WILL BE REDUCED TO 12% (AND 15% ABOVE REVENUE OF $65 MILLION) OF NET SALES FROM 25% - 35% OF NET SALES.

BIOFRONTERA INC. ANNOUNCES MAJOR RESTRUCTURING OF RELATIONSHIP WITH BIOFRONTERA AG BACKED BY $11 MILLION INVESTMENT

WOBURN, MASS., JUNE 11, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), CONFIRMS A DISCLOSURE BY THE MANAGEMENT BOARD OF BIOFRONTERA AG ON JUNE 10, 2025, ACCORDING TO WHICH THE TWO COMPANIES ARE IN NEGOTIATIONS REGARDING A POSSIBLE COMBINATION OF THE TWO COMPANIES OR AN ADJUSTMENT OF THE LICENSE AND SUPPLY AGREEMENT BETWEEN THEM. THE LATTER COULD RESULT IN THE TRANSFER OF CERTAIN RIGHTS AND OBLIGATIONS FROM BIOFRONTERA AG TO BIOFRONTERA INC. AND A REDUCTION IN THE TRANSFER PRICE FOR BIOFRONTERA INC.'S LICENSED PRODUCTS SOLD IN THE US.

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

WOBURN, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THE INCLUSION OF THE PATENT FOR ITS PROPYLENE GLYCOL-FREE FORMULATION OF AMELUZ NANOEMULSION GEL IN THE US FOOD AND DRUG ADMINISTRATION'S (FDA'S) PUBLICATION APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS (COMMONLY KNOWN AS THE ORANGE BOOK).

BIOFRONTERA INC. ANNOUNCES PATENT FOR PROPYLENE GLYCOL-FREE FORMULA OF AMELUZ (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% NOW LISTED IN FDA ORANGE BOOK

CONFERENCE CALL BEGINS AT 10:00 A.M. EASTERN TIME ON FRIDAY, MAY 16, 2025 WOBURN, MASS.

BIOFRONTERA INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

WOBURN, MASS., MAY 15, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), RECEIVED CONFIRMATION THAT THE UPDATED FORMULATION OF THE AMELUZ NANOEMULSION GEL WITHOUT PROPYLENE GLYCOL RECEIVED PATENT APPROVAL THROUGH TO DECEMBER 2043. THE FORMULATION WAS EARLIER ACCEPTED FOR USE IN AMELUZ BY THE US FOOD AND DRUG ADMINISTRATION (FDA) AND IS IN USE SINCE 2024. IN ADDITION TO THIS LONG-LASTING PROTECTION OF AMELUZ AGAINST GENERIC COMPETITION, BIOFRONTERA TODAY ANNOUNCED THE SUCCESSFUL ENROLLMENT OF THE FINAL PATIENT IN ITS PHASE 2B CLINICAL TRIAL EVALUATING AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS.

BIOFRONTERA INC. ANNOUNCES NEW PATENT PROTECTION ON AMELUZ UNTIL 2043 AND THE COMPLETION OF PATIENT ENROLLMENT IN PHASE 2B STUDY OF AMELUZ (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS

WOBURN, MA / ACCESS NEWSWIRE / MAY 6, 2025 / BIOFRONTERA INC. (NASDAQ:BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION OF DERMATOLOGICAL PRODUCTS, ANNOUNCES IT WILL REPORT FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 ON THURSDAY, MAY 15, 2025. THE RESULTS WILL BE RELEASED AFTER THE MARKET CLOSE ON THURSDAY, MAY 15 AND THE COMPANY WILL HOST A CONFERENCE CALL ON FRIDAY, MAY 16 AT 10:00AM EASTERN TIME.

Biofrontera Inc.

BFRI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biofrontera Inc.

BFRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BFRI